NIH RFA · NIDA · R61, R33
RFA-DA-27-016: HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The goal of this notice of funding opportunity (NOFO) is to address the opioid crisis and/or overdose events by supporting action-oriented research, accelerating the translation of addiction epidemiology, prevention, treatment services, and recovery research to practice. Proposed studies may target the individual, provider, organizational, community, or system level. This initiative prioritizes replicable and scalable approaches for accelerating the routine use of effective, evidence-based prevention, treatment and recovery interventions and services. The translation of research to practice and research relevant to chronic pain comorbid with substance use is also a priority. Research may…
- NOFO number
- RFA-DA-27-016
- Type
- RFA
- Activity code
- R61R33
- Primary institute
- NIDA · National Institute on Drug Abuse
- Clinical trials
- Optional
- Posted
- Jun 4, 2026
- Opens
- Jun 10, 2026
- Expires
- Feb 10, 2029
RFA-DA-27-016 due dates
7 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| July 10, 2026 | July 10, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 09, 2026 | October 09, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 10, 2027 | February 10, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 09, 2027 | June 09, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 13, 2027 | October 13, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
| February 10, 2028 | February 10, 2028 | Not Applicable | July 2028 | October 2028 | December 2028 |
| June 09, 2028 | June 09, 2028 | Not Applicable | November 2028 | January 2029 | April 2029 |
| October 10, 2028 | October 10, 2028 | Not Applicable | March 2029 | May 2029 | July 2029 |
| February 09, 2029 | February 09, 2029 | Not Applicable | July 2029 | October 2029 | December 2029 |
Funded projects
NIH RePORTER lists no awards under RFA-DA-27-016 in FY2022–FY2026, and it is a new NOFO rather than a reissue. Awards usually appear a few months after the first review cycle.
Participating institutes
4 NIH institutes and offices take applications under RFA-DA-27-016. Contact the program officer at the institute that fits your research before applying.
- NIDA · National Institute on Drug Abuse
- NIA · National Institute on Aging
- NIAAA · National Institute on Alcohol Abuse and Alcoholism
- NCCIH · National Center for Complementary and Integrative Health
Related notices
NIH lists no related notices for RFA-DA-27-016 yet.
Award terms
- Application types allowed
- New Resubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets must reflect the actual needs of the proposed project. The R61 phase is limited to a budget of no more than 350,000 in direct costs per year and the R33 phase is limited to a budget of no more than 750,000 in direct costs per year.
- Project period
- The scope of the project should determine the project period for each phase. The maximum period of the combined R61 and R33 phases is 6 years, with a maximum of 2 years for the R61 phase and maximum of 5 years for the R33 phase of the project. Applicants are encouraged to streamline the project period to complete the research as efficiently as possible. Applicants proposing R33 phases that exceed…
- Funds available and number of awards
- The NIH HEAL Initiative intends to commit an estimated total of 6,000,000 to fund 12 awards in FY2027. Awards pursuant to this funding opportunity are contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Other open NOFOs for R61, R33
- PAR-27-053Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)NIDA · next due Nov 2, 2026
- RFA-MH-27-125Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)NIMH · next due Nov 9, 2026
- RFA-AI-27-018Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)NIAID · next due Nov 10, 2026
- RFA-DC-27-004BRAIN Initiative: Exploratory Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (R61 Clinical Trial Not Allowed)NIDCD · next due Feb 11, 2027
- PAR-25-158Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)NIAAA · next due Oct 19, 2026
- PAR-25-269NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)NCCIH · next due Oct 20, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.